Medtronic PLC (NYSE:MDT) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts have given Medtronic PLC a consensus rating of "Moderate Buy", with an average target price of $102.82 based on 23 analysts' assessments.
• Recent insider transactions include Director William R. Jellison purchasing 2,500 shares, increasing his stake by 100%, while EVP Harry Skip Kiil sold 8,605 shares, reflecting a 19.46% decrease in his ownership.
• Medtronic recently reported earnings of $1.26 per share, exceeding expectations and showing a 7.7% year-over-year revenue increase, amounting to $8.58 billion for the quarter.

Shares of Medtronic PLC (NYSE:MDT - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty-three analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $102.8235.

MDT has been the subject of several analyst reports. Daiwa Capital Markets boosted their price objective on Medtronic from $101.00 to $104.00 and gave the company a "buy" rating in a report on Friday, September 12th. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of Medtronic in a report on Wednesday, October 8th. Sanford C. Bernstein upped their price target on Medtronic from $97.00 to $98.00 and gave the stock an "outperform" rating in a report on Wednesday, August 20th. William Blair raised Medtronic to a "hold" rating in a report on Friday, July 11th. Finally, Citigroup upped their price target on Medtronic from $101.00 to $112.00 and gave the stock a "buy" rating in a report on Tuesday, October 7th.

Insider Transactions at Medtronic

In other news, Director William R. Jellison acquired 2,500 shares of the business's stock in a transaction on Monday, August 25th. The stock was bought at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the purchase, the director owned 5,000 shares in the company, valued at approximately $461,850. This represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the business's stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president owned 35,615 shares of the company's stock, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.26% of the company's stock.

Institutional Investors Weigh In On Medtronic

Several large investors have recently bought and sold shares of MDT. Brighton Jones LLC increased its stake in Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company's stock worth $3,194,000 after buying an additional 37,265 shares in the last quarter. GAMMA Investing LLC increased its stake in Medtronic by 41.1% during the 1st quarter. GAMMA Investing LLC now owns 15,882 shares of the medical technology company's stock worth $1,427,000 after buying an additional 4,626 shares in the last quarter. Golden State Wealth Management LLC increased its stake in Medtronic by 180.8% during the 1st quarter. Golden State Wealth Management LLC now owns 2,752 shares of the medical technology company's stock worth $247,000 after buying an additional 1,772 shares in the last quarter. Perigon Wealth Management LLC increased its holdings in shares of Medtronic by 7.5% in the first quarter. Perigon Wealth Management LLC now owns 13,735 shares of the medical technology company's stock valued at $1,234,000 after purchasing an additional 953 shares during the last quarter. Finally, Western Wealth Management LLC increased its holdings in shares of Medtronic by 14.9% in the first quarter. Western Wealth Management LLC now owns 5,628 shares of the medical technology company's stock valued at $506,000 after purchasing an additional 730 shares during the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Stock Performance

Shares of MDT stock opened at $93.76 on Friday. The stock has a market cap of $120.26 billion, a PE ratio of 25.83, a price-to-earnings-growth ratio of 2.48 and a beta of 0.78. The business has a 50-day simple moving average of $94.32 and a 200-day simple moving average of $89.33. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. Medtronic has a 52-week low of $79.29 and a 52-week high of $99.37.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.03. The business had revenue of $8.58 billion during the quarter, compared to analysts' expectations of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The company's revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, equities analysts expect that Medtronic will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 17th. Investors of record on Friday, September 26th were issued a $0.71 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a yield of 3.0%. Medtronic's dividend payout ratio is presently 78.24%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.